August 7, 2018
New investigational therapies in the pipeline that address multiple myelomainclude both small-molecule and immunotherapeutic approaches — and in some cases, a combination of the two. Drugs that increase the visibility of tumors to the immune system, used in combination with additional medications that bolster the immune system, will be the future focus in the management of...
Continue Reading
When patients with multiple myeloma become refractory to lenalidomide (Revlimid) or bortezomib (Velcade), or have penta-refractory disease, there have been limited options left for treatment, according to Suman Kambhampati, MD. Recent studies presented at the 2018 ASCO Annual Meeting indicate that meaningful changes may be on the horizon. Notably, the anti-BCMA CAR T-cell therapy bb2121...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand